Mereo BioPharma
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 33
- Market Cap
- $738.4M
- Introduction
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in ...
Ultragenyx Pharmaceutical Inc. received Breakthrough Therapy Designation from the FDA for setrusumab (UX143) to reduce fracture risk in osteogenesis imperfecta (OI) Type I, III, or IV patients aged 2 and older. The designation is based on positive Phase 2 study results showing a decrease in fracture rate.
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
Mereo BioPharma's CEO, Dr. Denise Scots-Knight, will participate in a Fireside Chat at the 2024 Cantor Global Healthcare Conference on September 18. The company focuses on rare diseases, with product candidates setrusumab for osteogenesis imperfecta and alvelestat for severe alpha-1 antitrypsin deficiency-associated lung disease. Mereo also has oncology candidates etigilimab and navicixizumab in development.
© Copyright 2024. All Rights Reserved by MedPath